| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Crenigacestat | JSMD-194; LY-3039478; BMS-986405 | Phase 1 Clinical | Eli Lilly And Company | Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colonic Neoplasms; Leiomyosarcoma; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Multiple Myeloma; Neoplasm Metastasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma; Solid tumours; Triple Negative Breast Neoplasms | Details |